Thomas John Charles
EVP, General Counsel
Thomas John Charles has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Jun 26, 2026.
On the most recent filing, Thomas John Charles is listed as EVP, General Counsel at Krystal Biotech, Inc. Inside the rolling window, Thomas John Charles reported no open-market purchases and 2 open-market sales totaling $541K in KRYS. The largest disclosed transaction in the window is a sale of 1,000 KRYS shares on Jun 25, 2026, worth $347K.
Companies traded
Other insiders at KRYS
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$541K
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Thomas John Charles made?
Thomas John Charles has filed 2 SEC Form 4 filings (3 transaction rows) across 1 company since 2026.
Which companies does Thomas John Charles trade?
Thomas John Charles has filed SEC Form 4 disclosures for 1 company, including KRYS.
When was Thomas John Charles's most recent SEC Form 4 filing?
Thomas John Charles's most recent SEC Form 4 filing on Tracefour is dated Jun 26, 2026.
What is Thomas John Charles's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Thomas John Charles is listed as EVP, General Counsel.
What is Thomas John Charles's total buy and sell value in the current window?
Inside the rolling retention window, Thomas John Charles bought $0 and sold $541K based on SEC Form 4 filings.
What was Thomas John Charles's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 1,000 KRYS shares on 2026-06-25, worth $347K, per SEC Form 4 filings.